ClinicalTrials.gg
RecruitingNCT04257487JasonUpdated Jul 31, 2024

Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)

A Phase 3 interventional study of Sulodexide and Sulodexide and placebo in Venous Thromboembolism, Anticoagulant and Elderly, sponsored by Arianna Anticoagulazione Foundation. Recruiting at 1 site in Italy. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2024-07-31.

Sponsored by Arianna Anticoagulazione Foundation · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Dec 2020; still recruiting 5 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,455
Allocation
Randomized
Ages
75 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 74 studies in Venous Thromboembolism with a site in Italy — 10 open to participants now, 13 under way, 3 of them phase 3. Venous Thromboembolism · Italy.

Planned enrollment
17th of 50
1,455 · median 839
Started
2020
with 2 others
Phase 3
32 of 74
3 open now
Primary completion
2025-12
later than 3 of 12 live
Registered
60th of 74
by date

Among the 74 studies in Venous Thromboembolism with a site in Italy, this one is the 17th largest by planned enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2020, is one of 32 in phase 3, reaches primary completion later than 3 of the 12 other live ones, and was the 60th registered.

Venous Thromboembolism

714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

10 of the 74 studies in Venous Thromboembolism with a site in Italy are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 75 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Venous Thromboembolism with a site in Italy, or all of them as a file.
02

Study summary

The study aims at optimizing extended management of elderly patients (> 75 years) with at least one of the known bleeding risk factor, who suffered from first episode of venous thromboembolism of the lower extremity (proximal deep vein thrombosis with or without pulmonary embolism) (VTE). Patients were randomized to receive three different treatment: Sulodexide 250 mg BIS in die; Sulodexide 500 BID in die or indistinguishable placebo to verify the efficacy and safety of extended treatment for 12 months with Sulodexide (Vessel®) in the secondary prevention of Deep Vein Thrombosis / Pulmonary Embolism (DVT/PE) recurrence.

Read the detailed description

This prospective cohort study aims to assess the efficacy and safety of the extended treatment with Sulodexide (Vessel®) in the secondary prevention of DVT / PE recurrence in elderly outpatients (≥ 75 years old at the time of inclusion) ), with at least one of the known bleeding risk factor, who had a first episode of lower extremity proximal DVT and / or PE, idiopathic or associated with weak or removed risk factors, and who have received standard treatment with any oral anticoagulant drug lasting at least 3 months. The study seeks to verify the safety of the Sulodexide therapy, demonstrating non-inferiority compared to placebo, with an incidence of major bleeding around 1% (upper confidence limit not > 3%).

03

Conditions studied

  • Venous Thromboembolism
  • Anticoagulant
  • Elderly

Keywords

  • Venous thromboembolism
  • Elderly
  • Sulodexide
04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with a first event of proximal lower extremity DVT and / or PE, idiopathic or associated with weak or removed risk factors.
  2. Patients aged ≥75 years at the time of enrolment
  3. Patients with at least one of the known risk factors of bleeding (APPENDIX 1):

    1. Hypertension
    2. Renal failure
    3. Thrombocytopenia
    4. Diabetes
    5. Antiplatelet therapy (ASA maximum 140 mg/die)
    6. Frequent falls (>2 /years)
    7. Nonsteroidal anti-inflammatory drug
    8. Liver failure
    9. Previous Stroke
    10. Anemia
    11. Poor anticoagulant control
    12. Alcohol abuse
  4. Patients of both sexes.
  5. Patients who at the time of enrolment have already undergone a period of anticoagulant therapy (AT, with any medication) of at least 3 months and the therapy has not been suspended for more than 30 days.
  6. Patients with no other AT indications.
  7. Patients capable and able to provide

Exclusion criteria

Exclusion Criteria:

  1. Patients aged \<75 years at the time of the recruitment visit.
  2. "Provoked" index event, which occurred:

    • Within 3 months of surgery or major trauma,
    • Bed Rest > 4 days,
    • Cast / immobility within 3 months.
  3. Index event represented by severe PE, with life threatening risk or treated with thrombolytic therapy.
  4. Index event represented by isolated distal DVT or superficial venous thrombosis.
  5. Thrombotic event in sites other than the deep proximal veins of the lower limbs.
  6. Anticoagulant therapy for less than 3 months at the time of enrolment.
  7. Discontinuation of anticoagulant therapy for over thirty days at the time of enrolment
  8. Recurrent episodes of DVT ± PE
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,455 participants (estimated)

Study arms

  • Active comparator
    Treatment A

    Sulodexide (Vessel) 2 capsules of 250 LSU BID, for 12 months

    Drug: Sulodexide

  • Active comparator
    Treatment B

    Sulodexide (Vessel) 1 capsule of 250 LSU and 1 indistinguishable placebo capsule BID., for 12 months

    Drug: Sulodexide and placebo · Drug: Placebo

  • Placebo comparator
    Treatment C

    2 indistinguishable placebo capsules BID, for 12 months

    Drug: Placebo

Interventions

  • DrugGlucuronyl glucosamine glycan sulfateStudies of Glucuronyl glucosamine glycan sulfateGlucuronyl glucosamine glycan sulfate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    2 soft capsules of Vessel® 250 LSU BID for 12 months

    Also known as: VESSEL®

  • DrugSulodexide and placebo

    1 soft capsule of Vessel® 250 LSU and 1 soft capsule of placebo BID for 12 months

    Also known as: VESSEL® and placebo

  • DrugPlacebo

    Sugar pill manufactured to mimic sulodexide 250 LSU

    Also known as: 2 soft capsule of placebo BDI for 12 months

06

What researchers measure

Primary outcomes

  1. Number and rate of patients with confirmed recurrent VTE and VTE-related death (efficacy).

    The occurrence of proximal deep vein thrombosis with or without pulmonary embolism (new or recurrent episode) wil be recorded in all patients

    Time frame: From date of enrollment until the date of first documented event assessed up to 12 months

  2. Number and rate of major Bleeding events (defined according to International Society on Thrombosis and Haemostasis guidelines (safety)

    Fatal bleeding; intracranial; intraspinal; intraocular; pericardial; intra-articular; intramuscular with compartment syndrome; retroperitoneal,; acute clinically overt bleeding will be recorded in all patients

    Time frame: From date of enrollment until the date of first documented event assessed up to 12 months

Secondary outcomes

  1. Number of and rate of thromboembolic events

    Transient ischemic attack (TIA), Stroke, Myocardial infarction will be recorded in all patients

    Time frame: From date of enrollment until the date of first documented event assessed up to 12 months

  2. Presence of severe post-thrombotic syndrome according to Villalta Score

    Patient with deep vein thrombosis as index event will be evaluated, at the and of follow-up, applying Villalta score, commonly used to diagnose post-thrombotic syndrome in the subacute phase of thrombosis. The presence of venous ulcer of the leg or a score \> of 15 points indicate the occurrence of severe post-thrombotic syndrome. The maximum score is 33. The score from 5 to 9 points indicate mild post-thrombotic syndrome and from 10 to 15 points indicate moderate post-thrombotic syndrome

    Time frame: 12 months

  3. Number and rate of non major bleeding complications

    In all patients will be recorded any sign or symptom of hemorrhage that does not fit the criteria for the definition of major bleeding but does meet at least one of the following criteria: 1)requiring medical intervention by a healthcare professional; 2) leading to hospitalization or increased level of care;3) prompting a face to face evaluation

    Time frame: From date of enrollment until the date of first documented event assessed up to 12 months

  4. Number and rate of dead patients (overall mortality)

    VTE-related death; cardiovascular related-death; bleeding-related death; death for: cancer, infectious disease and unknown cause; sudden death will be recorded in all patients

    Time frame: From date of enrollment until the date of first documented event assessed up to 12 months

07

Study locations

1 of 1 sites recruiting
  • Corrado Lodigiani
    Rozzano, 20089, Italy
    Recruiting
08

References and documents

Publications

  • Palareti G, Legnani C, Antonucci E, Zorzi S, Bignamini AA, Lodigiani C, Tosetto A, Bertu L, Pengo V, Testa S, Ageno W, Prisco D, Prandoni P, Poli D. Design and rationale of a randomized, placebo-controlled trial on the efficacy and safety of sulodexide for extended treatment in elderly patients after a first venous thromboembolism. Intern Emerg Med. 2021 Mar;16(2):359-368. doi: 10.1007/s11739-020-02381-5. Epub 2020 May 25. PubMed 32451933 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2020 (actual). Primary completion is estimated for Dec 2025, 60 months after the start.

Of 47 phase 3 interventional studies under Venous Thromboembolism, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 60 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2020
First posted
Feb 6, 2020
StartActual
Dec 21, 2020
Primary completionEst.
Dec 31, 2025
CompletionEst.
Jan 2, 2027
Last update
Jul 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04257487
Lead sponsor
Arianna Anticoagulazione Foundation
Responsible party
Sponsor
First posted
Feb 6, 2020
Start date
Dec 21, 2020
Primary completion
Dec 31, 2025 (estimated)
Completion
Jan 2, 2027 (estimated)
Last update
Jul 31, 2024

Study contacts

Cristina Legnani, BSc, PhD
Contact
c.legnani@fondazionearianna.org
0039 051 2812339
Emilia Antonucci, CR
Contact
e.antonucci@fondazionearianna.org
0039 051 4291116
Corrado Lodigiani, MD,PhD
study chair · IRCCS Humanitas, Rozzano (Milano)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glucuronyl glucosamine glycan sulfate

Start the discussion